China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026)
China Pharma Holdings (CPHI) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 | -111.96% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.11% |
| Dec 31, 2025 | -45.73% |
| Sep 30, 2025 | -529.70% |
| Jun 30, 2025 | 522.13% |
| Mar 31, 2025 | 77.44% |
| Dec 31, 2024 | 1,139.96% |
| Sep 30, 2024 | -104.01% |
| Jun 30, 2024 | 65.68% |
| Mar 31, 2024 | 58.57% |
| Dec 31, 2023 | -104.39% |
| Sep 30, 2023 | 2,911.59% |
| Jun 30, 2023 | 58.37% |
| Mar 31, 2023 | -60.33% |
| Dec 31, 2022 | 398.22% |
| Sep 30, 2022 | 96.14% |
| Jun 30, 2022 | -175.31% |
| Mar 31, 2022 | -218.09% |
| Dec 31, 2021 | -136.16% |
| Sep 30, 2021 | -79.16% |
| Jun 30, 2021 | 268.49% |